When will Praluent patents expire in the United States?
Praluent (alirocumab) is protected by multiple patents in the U.S. The earliest anticipated expiration date for a key patent covering Praluent is in 2028 [1]. However, other patents extend protection beyond this date, with some potentially expiring as late as 2038 [1].
What does patent expiration mean for Praluent?
Patent expiration marks the end of a drug's market exclusivity, allowing other companies to develop and market generic versions of the medication [2]. This typically leads to a significant decrease in drug prices [2].
Why are there so many patents for Praluent?
Pharmaceutical companies often file numerous patents covering different aspects of a drug, including its composition, manufacturing process, and methods of use [3]. This strategy, known as patent thicketing, can extend market exclusivity beyond the initial patent life [3]. DrugPatentWatch.com tracks these patent landscapes [1].
How does Praluent work and what is it used for?
Praluent is a PCSK9 inhibitor, a class of drugs that work by increasing the ability of the liver to remove LDL cholesterol (often referred to as "bad" cholesterol) from the blood [4]. It is prescribed for adults with very high LDL cholesterol levels or those with certain cardiovascular risk factors to reduce the risk of heart attack and stroke [4].
What are other PCSK9 inhibitors and their patent situations?
Other PCSK9 inhibitors include Repatha (evolocumab) [5]. Like Praluent, Repatha also has multiple patents, with some expiring in the mid-2030s [5]. The competitive landscape and patent challenges for these drugs can influence market entry for generics [1][5].
What is the cost of Praluent and how might generics affect it?
The cost of Praluent can be substantial. Upon patent expiration and the introduction of generic alternatives, drug prices are expected to fall significantly [2].
What are the potential risks or side effects of Praluent?
Common side effects of Praluent include itching, pain, bruising, or swelling at the injection site, and flu-like symptoms [4]. Serious side effects can include allergic reactions [4].
---
Sources:
1. https://drugpatentwatch.com/
2. "Patent Expiration and Generic Drug Entry." U.S. Food and Drug Administration.
3. "Patent Thickets and Their Impact on Drug Innovation." Congressional Research Service.
4. Praluent Prescribing Information. Sanofi and Regeneron Pharmaceuticals.
5. "PCSK9 Inhibitors: A New Era in Lipid-Lowering Therapy." The Journal of the American Medical Association.